UK Dementia Research Institute at UCL, London, UK.
Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
EMBO Mol Med. 2021 Aug 9;13(8):e14781. doi: 10.15252/emmm.202114781. Epub 2021 Aug 2.
On 7 June the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years-and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.
6 月 7 日，FDA 批准了 aducanumab，这是近 20 年来首款用于治疗阿尔茨海默病的新药——值得注意的是，这也是首款具有潜在疾病修饰机制的治疗这种破坏性疾病的药物，即从大脑中清除β-淀粉样蛋白（或 Aβ）斑块。
